Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.
Aged
Aged, 80 and over
Alendronate
/ adverse effects
Bone Density Conservation Agents
/ adverse effects
Case-Control Studies
Denmark
/ epidemiology
Diabetes Mellitus, Type 2
/ chemically induced
Diphosphonates
/ adverse effects
Female
Humans
Incidence
Male
Middle Aged
Osteoporosis
/ drug therapy
Registries
alendronate
bisphosphonate
bone
diabetes
type 2 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
09
2021
accepted:
27
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
17
2
2022
Statut:
epublish
Résumé
A link has been proposed between glucose homeostasis and bone metabolism. Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate. We conducted a population-based nested case-control study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. All cases with a diagnosis of type 2 diabetes between 2008 and 2018 were matched on sex and age with 3 randomly selected controls by incidence-density sampling. Exposure was defined as ever use of alendronate and further grouped as effective and compliant use. ORs were calculated by conditional logistic regression analysis with adjustment for several confounders and test for trend for dose-response relationship. We included 163,588 patients with type 2 diabetes and 490,764 matched control subjects with a mean age of 67 years and 55% male subjects. The odds of developing type 2 diabetes were lower among ever users of alendronate (multiple adjusted OR: 0.64 [95% CI 0.62-0.66]). A test for trend suggested a dose-response relationship between longer effective use of alendronate and lower risk of type 2 diabetes. These results suggest a possible protective effect of alendronate in a dose-dependent manner against development of type 2 diabetes.
Identifiants
pubmed: 34867816
doi: 10.3389/fendo.2021.771426
pmc: PMC8640922
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Alendronate
X1J18R4W8P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
771426Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Viggers, Al-Mashhadi, Starup-Linde and Vestergaard.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Epidemiol. 2012;4:303-13
pubmed: 23204870
Diabetes Care. 2018 May;41(5):971-978
pubmed: 29348194
Osteoporos Int. 1993;3 Suppl 3:S13-6
pubmed: 8298197
Diabetes Care. 2020 Jun;43(6):1209-1218
pubmed: 32238426
Osteoporos Int. 2018 Oct;29(10):2243-2250
pubmed: 29946757
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
J Physiol Biochem. 2021 Nov;77(4):601-611
pubmed: 34302624
Diabetes Res Clin Pract. 2017 Jan;123:199-208
pubmed: 28056431
Diabetes Metab Res Rev. 2020 Jan;36(1):e3225
pubmed: 31647163
Dan Med Bull. 2001 Feb;48(1):33-7
pubmed: 11258150
Diabetes Obes Metab. 2016 Sep;18(9):875-81
pubmed: 27097832
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Am J Epidemiol. 1992 May 1;135(9):1019-28
pubmed: 1595688
PLoS One. 2015 Apr 13;10(4):e0123279
pubmed: 25874962
JBMR Plus. 2020 Sep 29;4(11):e10412
pubmed: 33210064
Diabetes Obes Metab. 2020 Sep;22(9):1586-1597
pubmed: 32329136
Ugeskr Laeger. 1995 Jun 26;157(26):3741-5
pubmed: 7631448
Calcif Tissue Int. 2011 Oct;89(4):265-70
pubmed: 21710315
Int J Risk Saf Med. 1997;10(3):203-5
pubmed: 23511375
Osteoporos Int. 2007 Dec;18(12):1583-93
pubmed: 17566814
J Diabetes Investig. 2019 May;10(3):731-737
pubmed: 30267620
Calcif Tissue Int. 2010 Jun;86(6):421-35
pubmed: 20407762
Bone. 2008 Jul;43(1):40-47
pubmed: 18486585
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263
Arch Gerontol Geriatr. 2002 Mar-Apr;34(2):117-22
pubmed: 14764315
Medicine (Baltimore). 2017 Mar;96(12):e5290
pubmed: 28328798
J Bone Miner Res. 2013 Jun;28(6):1348-54
pubmed: 23322676
Acta Diabetol. 2020 May;57(5):549-558
pubmed: 31754819
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41
pubmed: 21775349
Health Rep. 2013 Jan;24(1):3-9
pubmed: 24259111
Bone. 2012 Feb;50(2):568-75
pubmed: 21550430
Maturitas. 2000 Oct 31;36(3):181-93
pubmed: 11063900
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Clin Epidemiol. 2018 Aug 16;10:981-989
pubmed: 30147377
Science. 2000 Mar 31;287(5462):2398-9
pubmed: 10766613
J Clin Endocrinol Metab. 2015 May;100(5):1933-40
pubmed: 25695881